Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2026-02-26 00:00:00 ET · period of report 2026-02-24 · accession 0001193125-26-078718 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-02-26 | 2026-02-24+ | NAMS | Davidson Michael H. | CEO, Dir | M - OptEx | — | +306.3K | 643.2K | +91% | — |
| DMT | 2026-02-26 | 2026-02-24+ | NAMS | Davidson Michael H. | CEO, Dir | S - Sale+OE | $34.53 | -306.3K | 174.1K | -64% | -$10.58M |
| DMT | 2026-02-26 | 2026-02-24+ | NAMS | Davidson Michael H. | CEO, Dir | M - OptEx | $0.00 | -306.3K | 866.3K | -26% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-02-24 | M | A | 64,708 | — | 524,567 | D | — | — | (F1) The exercise price of the option is EUR 1.16392. |
| 2 | Common | Ordinary Shares | 2026-02-24 | S | D | 61,547 | $36.13 | 463,020 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.43 to $36.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 3 | Common | Ordinary Shares | 2026-02-24 | S | D | 3,161 | $36.46 | 459,859 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.43 to $36.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 4 | Common | Ordinary Shares | 2026-02-25 | M | A | 58,253 | — | 518,112 | D | — | — | (F1) The exercise price of the option is EUR 1.16392. |
| 5 | Common | Ordinary Shares | 2026-02-25 | S | D | 46,517 | $35.11 | 471,595 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.57 to $35.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 6 | Common | Ordinary Shares | 2026-02-25 | S | D | 10,436 | $35.96 | 461,159 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.57 to $36.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 7 | Common | Ordinary Shares | 2026-02-25 | S | D | 1,300 | $36.68 | 459,859 | D | — | — | (F6) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.58 to $36.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 8 | Common | Ordinary Shares | 2026-02-26 | M | A | 183,332 | — | 643,191 | D | — | — | (F1) The exercise price of the option is EUR 1.16392. |
| 9 | Common | Ordinary Shares | 2026-02-26 | S | D | 165,408 | $33.63 | 477,783 | D | — | — | (F7) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.34 to $34.33 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 10 | Common | Ordinary Shares | 2026-02-26 | S | D | 17,924 | $34.44 | 174,144 | D | — | — | (F8) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.35 to $34.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. (F9) The amount reported in Column 5 reflects the transfer of 285,715 ordinary shares from the Reporting Person to the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the "GRAT") on February 26, 2026, which transfer was exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934. The Reporting Person is the sole annuitant and trustee of the GRAT. |
| 11 | Derivative | Option (right to buy) | 2026-02-26 | M | D | 183,332 | $0.00 | 682,974 | D | — · — to 2031-07-06 | 183,332 Ordinary Shares | (F1) The exercise price of the option is EUR 1.16392. (F10) The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
| 12 | Derivative | Option (right to buy) | 2026-02-24 | M | D | 64,708 | $0.00 | 924,559 | D | — · — to 2031-07-06 | 64,708 Ordinary Shares | (F1) The exercise price of the option is EUR 1.16392. (F10) The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
| 13 | Derivative | Option (right to buy) | 2026-02-25 | M | D | 58,253 | $0.00 | 866,306 | D | — · — to 2031-07-06 | 58,253 Ordinary Shares | (F1) The exercise price of the option is EUR 1.16392. (F10) The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |